/
Regenerative Biotech We are a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient s own stem cells to regenerate and restore function to damaged organs.
The business is unprofitable at the operating level (-982.24% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 63.7% YoY with margins expanding 814.5pp.
Negative free cash flow of -$4M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$885K
▲ +63.7% YoY
Net Income (TTM)
-$7M
▲ +11.2% YoY
Op. Margin
-774.12%
▲ +814.5pp YoY
ROIC
-463.58%
▲ +13.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▲ +21.1% YoY
Op. Cash Flow (TTM)
-$4M
▲ +21.1% YoY
Net Debt
-$131K
Net Cash Position
Cash & Equiv.
$419K
Continue Research